JPRN-UMIN000005130已完成2 期
Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission. - Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission. (DADI trial)
Epidemiological and Clinical Research Information Network (ECRIN)0 个研究点目标入组 50 人开始时间: 2011年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Concurrent malignancy other than CML 2.Women who are pregnant or breastfeeding 3. A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy 4.Subjects with T315I, F317L and V299L BCR-ABL point mutations 5.Subjects with clonal evolution
研究者
相似试验
招募中
2 期
Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.JPRN-UMIN000008999Epidemiological and Clinical Research Information Network(ECRIN)50
招募中
2 期
Imatinib discontinuation for Chronic Myelogenou Leukemia-Chronic Phase with 2 years complete molecular remission.Chronic Myelogenou Leukemia-Chronic Phase who have maintained complete molecular remission for at least 2 years.JPRN-UMIN000012472Epidemiological and Clinical Research Information Network (ECRIN)100
Unknown
2 期
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop TrialChronic Myeloid LeukemiaNCT01627132Shimousa Hematology Study Group50
尚未招募
不适用
To stop the use of Imatinib in CML-CP patientsCTRI/2019/07/020407DR BRA IRCH AIIMS
招募中
不适用
Stop imatinib or dasatinib study in CP-CML patients mainitaining complete molecular response for two yearschronic phase chronic myeloid leukemiaJPRN-UMIN000007944Tokyo Women's Medical University40